

2-6-6 JFW
Certificate of Mailing (37 C.F.R. §1.10);
I hereby certify that this correspondence is being
Transmitted via Express Mail (EV723989661US) to Mail
Stop: Amendment, Commissioner for Patents,
PO Box 1450, Alexandria, VA 22313-1450
on this 3rd day of February 2006.

s/ Rachel Potash
Rachel Potash

EV723989661US



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:
Peng Cho Tang, et al.

Serial No.: 10/714,399

Confirmation No.: 2032

Filed: November 17, 2003

For: TRICYCLIC QUINOXALINE
DERIVATIVES AS PROTEIN
TYROSINE KINASE INHIBITORS

Group Art Unit: 1624

Examiner: Thomas C. McKenzie

Mail Stop: Amendment
Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith are the following documents:

1. Response to Restriction Requirement
2. Return Postcard
3. Total Fee Due \$0.00

2 pages + duplicate;
1 postcard; and
Deposit Account.


Respectfully submitted,

Date: 02/03/2006

Vincent P. Liptak

Vincent P. Liptak
Agent For Applicants
Registration No. 53,225

Agouron Pharmaceuticals, Inc./A Pfizer Company
Patent Department
10777 Science Center Drive
San Diego, California 92121
Phone: (858) 622-7908
Fax: (858) 678-8233



Certificate of Mailing (37 C.F.R. §1.10):
I hereby certify that this correspondence is being
Transmitted via Express Mail (EV723989661US) to Mail
Stop: Amendment, Commissioner for Patents,
PO Box 1450, Alexandria, VA 22313-1450
on this 3rd day of February 2006.

s/

Rachel Potash
Rachel Potash

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:
Peng Cho Tang, et al.

Serial No.: 10/714,399

Confirmation No.: 2032

Filed: November 17, 2003

**For: TRICYCLIC QUINOXALINE
DERIVATIVES AS PROTEIN
TYROSINE KINASE INHIBITORS**

Group Art Unit: 1624

Examiner: Thomas C. McKenzie

Mail Stop AMENDMENT
Honorable Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

In a restriction requirement dated January 04, 2006, the Examiner required restriction under 35 U.S.C. § 121 between:

Group I: Claims parts of 1-14, drawn to fused oxazole compounds *etc.* of the formula of claim 1 with B = C and A and D = N, O, or S, classified in class 544, subclass 345.

Group II: Claims parts of 15-21, drawn to therapeutic uses of the fused imidazole compounds of the formula of claim 1 with B = C and A and D = N, classified in class 514, subclass 250.

Group III: Claims parts of 1-14, drawn to fused cyclopentadiene compounds of the formula of claim 1 with B = C and A = D = C, classified in class 544, subclass 344.

Group IV: Claims parts of 1-14, drawn to fused oxadiazole compounds *etc.* of the formula of claim 1 with B = N, O, or S and A and D = C, N, O, or S, classified in class 544, subclass 345.

Group V: Claims parts of 15-21, drawn to therapeutic uses of the fused furan *etc.* compounds of the formula of claim 1 with B = C and A and D = C, O, or S, classified in class 514, subclass 250.

Group VI: Claims parts of 15-21, drawn to therapeutic uses of the fused triazole *etc.* compounds of the formula of claim 1 with B = N, O, or S and A and D = C, N, O, or S, classified in class 514, subclass 250.

Applicants elect without traverse the claims of Group III, drawn to fused cyclopentadiene compounds of the formula of claim 1 with B = C and A = D = C, classified in class 544, subclass 344.

If any fees other than those submitted herewith are due in connection with this response, including the fee for any required extension of time (for which Applicants hereby petition), please charge such fees to Deposit Account No. 500329.

Respectfully submitted,

Date: 02/03/2006



Vincent P. Liptak
Agent For Applicants
Registration No. 53,225

Agouron Pharmaceuticals, Inc./A Pfizer Company
Patent Department
10777 Science Center Drive
San Diego, California 92121
Phone: (858) 622-3087
Fax: (858) 678-8233